Skip to main content
. Author manuscript; available in PMC: 2013 Aug 2.
Published in final edited form as: Immunol Invest. 2012;41(0):680–710. doi: 10.3109/08820139.2012.703745

Figure 7.

Figure 7

Comparisons with other RTKi’s fail to delineate the mechanism by which sunitinib decimates splenic MDSCs. A. Comparison targets for different RTKi’s. B,C, Sunitinib profoundly decreases splenic MDSCs in both 4T1 and CT26 models with minimal comparable impact from either imatinib (Gleevec) or vatalanib. Not shown: similar lack of impact from lestaurtinib, combined imatinib and vatalanib, or sorafenib. Maximially tolerated doses (MTDs) were determined for each agent and used in these comparisons.